Loading...
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome...
Na minha lista:
| Udgivet i: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066856/ https://ncbi.nlm.nih.gov/pubmed/27784993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S85050 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|